T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.